Register Now
Course Information

You Don’t Want to Miss Cleveland Clinic's Pulmonary Hypertension Summit 2017

New This Year in Cleveland

Precision Care in Lung Diseases is an optional one-day pre-symposium that will provide an update on pulmonary genomics in the areas of airway diseases, lung cancer, pulmonary hypertension, and interstitial lung disease. Pharmacogenetics has revolutionized patient care and the therapy of lung diseases in particular. While the practice of medicine continues to be limited to guidelines that treat all patients equally, precision medicine aims at tailoring medical therapy to the clinical and genetic characteristics of each patient. Attend this pre-symposium for an update on the rapidly evolving discipline of genomics and new advances that can be applied to your clinical practice.

Many clinicians care for survivors of acute pulmonary embolism without knowing that a proportion of these will develop chronic thromboembolic pulmonary hypertension (CTEPH). The Summit addresses this with a review of the evaluation, diagnosis, and therapy of pulmonary hypertension, CTEPH, and acute pulmonary embolism. In addition, the Summit will review the most recent advances in the context of challenges faced by physicians and other health care providers caring for these patients.

Be a part of the unique opportunity to learn from an international faculty and interact with colleagues throughout the United States. Take advantage of the opportunity and learn from shared experts broadcast between two locations – Cleveland, OH and Fort Lauderdale, FL.

Pulmonary Hypertension Summit Learning Objectives

  • Describe the properties of novel anticoagulants to be able to prescribe them according to specific patient characteristics
  • Identify the role of multidisciplinary teams in the management of acute pulmonary embolism
  • Explain the importance of the ventilationperfusion lung scan in the screening for chronic thromboembolic pulmonary hypertension (CTEPH)
  • Recognize when to refer patients with suspected or known CTEPH to specialized centers for surgical evaluation
  • Discuss the shift toward early and upfront combination therapy
  • Detail the expected adverse events associated with pulmonary hypertension therapeutics and discuss their management
  • Describe the frequency, severity, and treatment of pulmonary hypertension as a complication of chronic obstructive pulmonary disease and interstitial lung disease
  • Summarize the evidence base supporting recent clinical developments in the pathobiology, epidemiology, diagnosis, and treatment of acute and chronic pulmonary embolism
  • Discuss the pharmacoeconomics of pulmonary hypertension therapeutics and review new findings exploring cost effectiveness of care

Who Should Attend

These educational activities are directed to cardiologists, pulmonologists, critical care physicians, physician assistants, advanced practice nurses, researchers and other health care professionals.